{"analyses":[{"ciLowerLimit":"0.1","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"39.3","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Mean Difference (Final Values)","paramValue":"9.5"},{"ciLowerLimit":"0.0","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"35.9","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Mean Difference (Final Values)","paramValue":"11.6"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.3","upperLimit":"12.3","value":"9.5"},{"groupId":"OG001","lowerLimit":"8.6","upperLimit":"13.1","value":"11.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"166"},{"groupId":"OG001","value":"82"}],"units":"Participants"}],"description":"Overall survival (OS) was defined as time from randomization until death from any cause; Only descriptive analyses of OS were repeated in with the data as of the 02 JUL 2019.","dispersionType":"95% Confidence Interval","groups":[{"description":"Test drug: 6.5 mg/kg every 3 weeks; Intravenous (IV) infusion over 1 hour","id":"OG000","title":"Anetumab Ravtansine"},{"description":"Active comparator: 30 mg/m\\^2 once weekly","id":"OG001","title":"Vinorelbine"}],"paramType":"MEAN","populationDescription":"The secondary efficacy analysis (OS) was performed in the ITT (Intent-to-treat) analysis set.","reportingStatus":"POSTED","timeFrame":"Up to approx. 55 month (data cut-off: 02-JUL-2019) - Time from randomization until death from any cause","title":"Overall Survival (OS) - Addendum","type":"SECONDARY","unitOfMeasure":"months"}